Long Progression-free Survival with Afatinib in a Patient with EGFR-unknown Lung Adenocarcinoma after Erlotinib Failure: A Case Report
Maria Giuseppa Vitale(University of Modena and Reggio Emilia), Giacomo Cartenl(Ospedale Antonio Cardarelli), Manuela Otero(Ospedale Antonio Cardarelli), Sarah Scagliarini(Ospedale Antonio Cardarelli), Carmela Mocerino(Ospedale Antonio Cardarelli), Ferdinando Riccardi(Ospedale Antonio Cardarelli), Francesca Ambrosio(Azienda Ospedaliero-Universitaria Careggi), Carmela Barbato(Ospedale Antonio Cardarelli)
Cited by 2
Related Papers
First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial
|Journal of Clinical Oncology|2012|234
Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial
|Journal of Clinical Oncology|2017|186
Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study
|The Journal of Clinical Endocrinology & Metabolism|2019|180
Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study
|European Urology|2021|110
Real-World Study of Everolimus in Advanced Progressive Neuroendocrine Tumors
|The Oncologist|2014|103